The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HRMY | -15.5% | -12.01% | -2.52% | -23% |
| S&P | +17.45% | +75.43% | +11.88% | +100% |
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested, and everything changed.
The biotech company is looking for multiple successes in the coming years.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $243.78M | 21.1% |
| Gross Profit | $169.27M | 20.1% |
| Gross Margin | 69.44% | -0.6% |
| Market Cap | $2.16B | 9.8% |
| Market Cap / Employee | $7.36M | 0.0% |
| Employees | 293 | 9.3% |
| Net Income | $22.49M | -54.6% |
| EBITDA | $45.99M | -25.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $752.50M | 66.1% |
| Accounts Receivable | $96.79M | 16.6% |
| Inventory | 5.4 | -25.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $148.18M | -9.6% |
| Short Term Debt | $86.89M | 25.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 13.98% | -2.1% |
| Return On Invested Capital | 12.93% | 38.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $126.04M | 67.9% |
| Operating Free Cash Flow | $126.15M | 67.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 12.65 | 10.19 | 8.68 | 13.82 | 0.78% |
| Price to Book | 2.88 | 2.52 | 2.05 | 2.58 | -21.51% |
| Price to Sales | 2.61 | 2.39 | 1.96 | 2.53 | -9.77% |
| Price to Tangible Book Value | 3.47 | 2.96 | 2.36 | 2.91 | -29.10% |
| Price to Free Cash Flow TTM | 8.77 | 7.14 | 5.45 | 6.31 | -31.08% |
| Enterprise Value to EBITDA | 26.40 | 27.52 | 16.41 | 36.01 | 25.58% |
| Free Cash Flow Yield | 11.4% | 14.0% | 18.3% | 15.8% | 45.11% |
| Return on Equity | 24.7% | 27.6% | 25.9% | 20.8% | -19.69% |
| Total Debt | $207.02M | $209.16M | $227.06M | $235.07M | 0.82% |
No podcast episodes available.
HRMY earnings call for the period ending December 31, 2024.
HRMY earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
